Holen Sie sich die Stockscreener-App
318.30
1.19%
3.74
Handel nachbörslich:
318.00
-0.30
-0.09%
Schlusskurs vom Vortag:
$314.56
Offen:
$314.16
24-Stunden-Volumen:
360.78K
Relative Volume:
0.58
Marktkapitalisierung:
$22.41B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
96.87
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
+1.55%
1M Leistung:
-6.87%
6M Leistung:
+24.59%
1J Leistung:
+36.90%
1-Tages-Spanne:
$312.69
$323.69
1-Wochen-Bereich:
$310.07
$324.69
52-Wochen-Spanne:
$226.50
$353.50
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
318.30 | 22.14B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
133.27 | 228.66B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
96.24 | 140.69B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
370.00 | 139.51B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.54 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.36 | 42.83B | 5.69B | 1.41B | 577.90M | 6.9828 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Leerink Partners Adjusts Price Target on Insulet to $355 From $339, Maintains Outperform Rating - MarketScreener
Long term hold vs stop loss in Insulet CorporationDay Trade & Real-Time Price Movement Reports - newser.com
Full technical analysis of Insulet Corporation stockJuly 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
What Fibonacci levels say about Insulet Corporation reboundWeekly Gains Report & Capital Efficient Trade Techniques - newser.com
Why Insulet Corporation stock could outperform in 20252025 Market Overview & Trade Opportunity Analysis Reports - newser.com
Is Now The Time To Look At Buying Insulet Corporation (NASDAQ:PODD)? - 富途牛牛
Insulet (PODD) Valuation in Focus as Omnipod 5 Adoption Fuels Growth and Investor Optimism - Sahm
Pattern recognition hints at Insulet Corporation upsideQuarterly Market Review & Fast Gain Stock Trading Tips - newser.com
Insulet to Host Investor Day on November 20, 2025 - MarketScreener
How to monitor Insulet Corporation with trend dashboardsWeekly Trade Report & Community Consensus Picks - newser.com
Lobbying Update: $50,000 of INSULET CORPORATION lobbying was just disclosed - Quiver Quantitative
Insulet names new CEO, plans to lift full year guidance - MSN
Fifth Third Wealth Advisors LLC Invests $448,000 in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Sold by Aberdeen Group plc - MarketBeat
Insulet Corporation (PODD) Stock Analysis: Exploring a 15.3% Potential Upside with Robust Growth Prospects - DirectorsTalk Interviews
How to interpret RSI for Insulet Corporation stockEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Insulet Corporation stock trend outlook and recovery pathDividend Hike & Long-Term Growth Plans - newser.com
Insulet Corp. stock underperforms Tuesday when compared to competitors - MSN
Royal Bank Of Canada Raises Insulet (NASDAQ:PODD) Price Target to $365.00 - MarketBeat
Katamaran Capital LLP Has $1.22 Million Stock Position in Insulet Corporation $PODD - MarketBeat
Insulet (PODD) Valuation: Is There More Room to Run After 22% YTD Gain? - Yahoo Finance
Why analysts remain bullish on Insulet Corporation stockTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
What MACD signals say about Insulet CorporationJuly 2025 EndofMonth & Community Consensus Stock Picks - newser.com
What RSI levels show for Insulet Corporation (GOV) stockQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
RBC Lifts Price Target on Insulet to $365 From $350, Keeps Outperform Rating - MarketScreener
Blair William & Co. IL Sells 13,724 Shares of Insulet Corporation $PODD - MarketBeat
Truist Securities Reiterates Buy Rating on Insulet (PODD) Stock - MSN
Forecasting Insulet Corporation price range with options dataJuly 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
Is now a turning point for Insulet CorporationJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
Insulet (NASDAQ:PODD) Earns "Hold (C)" Rating from Weiss Ratings - MarketBeat
Insulet Opens Global Capability Center in Guadalajara - Mexico Business News
Insulet Corp. Experiences Evaluation Revision Amidst Mixed Market Dynamics and Strong Performance - Markets Mojo
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes" - sharewise.com
Insulet Corporation $PODD Shares Sold by SGL Investment Advisors Inc. - MarketBeat
Real time scanner hits for Insulet Corporation explainedRisk Management & Technical Pattern Alert System - newser.com
Highland Capital Management LLC Makes New Investment in Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Stock Analysis: Unpacking the 17% Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Insulet (PODD): A Fresh Look at Valuation Following Raised Guidance and Strong Q2 Growth - simplywall.st
How sentiment analysis helps forecast Insulet CorporationMarket Weekly Review & Fast Moving Market Watchlists - newser.com
Insulet Corporation $PODD Shares Acquired by ASR Vermogensbeheer N.V. - MarketBeat
What Analyst Watch Lists Suggest About Simplex Infrastructures Limiteds MomentumEarnings Revision Updates & Minimal Investment Trading Tips - earlytimes.in
Insulet (NASDAQ:PODD) Given New $370.00 Price Target at Rothschild & Co Redburn - MarketBeat
Franklin Street Advisors Inc. NC Makes New Investment in Insulet Corporation $PODD - MarketBeat
How Investors Are Reacting To Insulet (PODD) Raising Guidance After Surging Q2 Revenue and New Product Launch - simplywall.st
Rothschild & Co Redburn Adjusts Price Target on Insulet to $370 From $350, Maintains Buy Rating - MarketScreener
Can Omnipod Mango’s Bold Design Shift Signal a New Strategy for Insulet (PODD)? - simplywall.st
Lecap Asset Management Ltd. Takes Position in Insulet Corporation $PODD - MarketBeat
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):